US Pharma MarketingFrom drug development to M&A, Big Pharmas showcase AI’s ‘measurable impact’
From shrinking drug development timelines to scouting potential acquisitions, the recent run of first-quarter earnings results marked a shift for Big Pharma from AI hype to explaining how the techn The recent run of first-quarter earnings results marked a shift for Big Pharmas away from AI hype and toward explaining how the technology is being applied in practice. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards…
The recent run of first-quarter earnings results marked a shift for Big Pharmas away from AI hype and toward explaining how the technology is being applied in practice.
Source: FierceBiotech